# A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

> **NCT04282031** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beta Pharma (Suzhou) Co., Ltd.** · enrollment: 224 (estimated)

## Conditions studied

- Advanced Solid Tumor
- HR+/HER2- Breast Cancer

## Interventions

- **DRUG:** BPI-1178
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole
- **DRUG:** BPI-1178

## Key facts

- **NCT ID:** NCT04282031
- **Lead sponsor:** Beta Pharma (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-15
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04282031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04282031, "A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04282031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*